Patient groups specialising in bleeding disorders applaud the pharma industry's R&D, but want companies to be more socially responsible Patient groups specialising in bleeding disorders applaud pharma's innovation and product pipelines, but want companies to be more socially responsibleEmbargoed publication date: Tuesday, 24 July 2018, 6am GMTPress release based on the results of a new report: 'The Corporate Reputation of Pharma, 2017—the Perspective of Bleeding-Disorders Patient Groups', 2nd edition
Nine companies analysed in this report: Bayer I Biogen I CSL Behring I Grifols I Novo Nordisk I Octapharma I Pfizer I Roche (Genentech in the US) I Shire State of relationships between bleeding-disorders patient groups and the pharmaceutical industry The worldwide incidence of one of the most high profile of the bleeding disorders—haemophilia—is not well known. However, the US-based Centers for Disease Control (CDC) estimates that this particular condition affects more than 400,000 people, with as many as 75% of these individuals (mostly people living in poorer parts of the world) still receiving inadequate treatment for their bleeding disorder—or, indeed, no access to treatment at all. A large number of the comments made to the 2017 Corporate-Reputation survey by respondent bleeding-conditions patient groups underscored the problems associated with significant worldwide geographic inequities of bleeding-disorders treatments.
Although patient groups specialising in bleeding disorders held reservations about the pharmaceutical industry, the patient groups were also highly appreciative of both the innovation, and the high-quality products, provided by the industry:
Respondent patient groups specialising in bleeding disorders also offered helpful advice on how pharma companies might improve their corporate reputation. How pharma could improve ... 1. Exhibit corporate social responsibility in all communications with patients; be honest 2. Be more philanthropic, and support the healthcare infrastructure (including patient organisations) 3. Provide more support to patients, so that they can self manage their bleeding condition more effectively. 4. Listen more to patients, and thereby improve company R&D output. So, how did the companies perform at corporate reputation in 2017, in the viewpoints of patient groups specialising in bleeding disorders? Ranking at corporate reputation is measured by patient groups familiar with a company. Novo Nordisk was ranked overall 1st out of nine companies for corporate reputation in 2017 (as it had been in 2016) by the 30 respondent bleeding-disorders patient groups familiar with it. Novo Nordisk was specifically praised by one patient group in Ghana for helping streamlining its patient registry, and other activities. Roche (Genentech in the US) was ranked overall 2nd out of nine companies for corporate reputation in 2017 by bleeding-disorders patient groups claiming familiarity with it. (This performance represents a significant increase for Roche/Genentech on 2016, when the company was ranked only overall 8th out eight companies by patient groups specialising in bleeding disorders.) Biogen was ranked overall 3rd out of nine companies for corporate reputation in 2017 by the 17 bleeding-disorders patient groups familiar with it (on a par with the company’s performance at corporate reputation in 2016), even though Biogen had 2017’s smallest number of bleeding-disorders patient groups claiming familiarity with it (17). PROFILES OF THE 32 PATIENT GROUPS SPECIALISING IN BLEEDING DISORDERS, AND PARTICIPATING IN THE 2017 STUDY Country headquarters of 2017’s 32 respondent bleeding-disorders patient groups: Number FOR MORE INFORMATION ABOUT THIS REPORT, PLEASE USE THE CONTACT DETAILS BELOW-End of press release- |